Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.

Citation data:

Aging cell, ISSN: 1474-9726, Vol: 15, Issue: 5, Page: 872-84

Publication Year:
Usage 2691
Abstract Views 2556
Full Text Views 106
Clicks 28
Link-outs 1
Captures 115
Readers 79
Exports-Saves 36
Mentions 32
News Mentions 28
Blog Mentions 2
References 1
Comments 1
Social Media 919
Shares, Likes & Comments 872
Tweets 47
Citations 44
Citation Indexes 44
Reddit 22
Repository URL:
Strong, Randy; Miller, Richard A; Antebi, Adam; Astle, Clinton M; Bogue, Molly A; Denzel, Martin S; Fernandez, Elizabeth; Flurkey, Kevin; Hamilton, Karyn L; Lamming, Dudley W; Javors, Martin A; de Magalhães, João Pedro; Martinez, Paul Anthony; McCord, Joe M; Miller, Benjamin F; Müller, Michael; Nelson, James F; Ndukum, Juliet; Rainger, G Ed; Richardson, Arlan; Sabatini, David M; Salmon, Adam B; Simpkins, James W; Steegenga, Wilma T; Nadon, Nancy L; Harrison, David E Show More Hide
Wiley-Blackwell; Blackwell Pub.
Biochemistry, Genetics and Molecular Biology; Life Sciences; Medicine and Health Sciences
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin - the latter with and without rapamycin, and two drugs previously examined: 17-α-estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17-α-estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male-specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The α-glucosidase inhibitor, acarbose, at a concentration previously tested (1000 ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16 months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies.